Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Century Therapeutics (IPSC) Debt to Equity (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Debt to Equity for 3 consecutive years, with $0.05 as the latest value for Q3 2025.

  • On a quarterly basis, Debt to Equity changed N/A to $0.05 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.05, a N/A change, with the full-year FY2022 number at $0.03, changed N/A from a year prior.
  • Debt to Equity was $0.05 for Q3 2025 at Century Therapeutics, up from $0.04 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.05 in Q3 2025 to a low of $0.03 in Q1 2022.
  • A 3-year average of $0.03 and a median of $0.03 in 2022 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 43.39% in 2023; the steepest drop was 43.39% in 2023.
  • Century Therapeutics' Debt to Equity stood at $0.03 in 2022, then grew by 9.82% to $0.04 in 2023, then increased by 27.27% to $0.05 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Debt to Equity are $0.05 (Q3 2025), $0.04 (Q1 2023), and $0.03 (Q4 2022).